Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242264 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Shigella Vaccine and Challenge
A Phase 2 study of Shigella Infection and Immunisation, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 2
- Study locations
NCT04242264 is a Phase 2 study of Shigella Infection and Immunisation that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 69 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04242264, a Phase 2 study of Shigella Infection and Immunisation, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a trial to evaluate the safety, reactogenicity, immunogenicity and efficacy of a 10\^6 cfu dose of an oral live-attenuated S. sonnei vaccine candidate, WRSs2, in up to 120 healthy males and non-pregnant females aged 18-49, inclusive. This is a two-phase study, an outpatient WRSs2 vaccination phase and an inpatient S. sonnei 53G challenge phase. After the initiation of the study, two participants had Grade 3 diarrhea and/or vomiting in the days following vaccination. The vaccination dose was reduced to 5X10\^5, enrollment was changed to 2 arms and randomized 2:1 (vaccine: placebo). Participants with morbid obesity were excluded and weight loss medications prohibited. The Primary Objective of this study is to estimate combined vaccine efficacy of 2 doses of WRSs2 (10\^6 cfu or 5X10\^5 cfu) in preventing shigellosis, following challenge with S. sonnei strain 53G.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Shigella sonnei strain 53G
- BIOLOGICAL WRSs2
Study Locations (2)
Georgia
- The Hope Clinic of Emory University - Decatur
Ohio
- Cincinnati Children's Hospital Medical Center Vaccine Research Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2024-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04242264
The ClinicalTrials.gov registry entry for NCT04242264 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Shigella Infection appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04242264 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT04242264 about?
NCT04242264 is a clinical study titled "Phase 2 Shigella Vaccine and Challenge". This is a trial to evaluate the safety, reactogenicity, immunogenicity and efficacy of a 10\^6 cfu dose of an oral live-attenuated S. sonnei vaccine candidate, WRSs2, in up to 120 healthy males and non-pregnant females aged 18-49, inclusive. This is a two-phase study, an outpatient WRSs2 vaccination...
What is the current status of trial NCT04242264?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2022-10-12. Estimated completion is 2024-07-08.
What conditions does trial NCT04242264 study?
This clinical trial studies the following conditions: Shigella Infection, Immunisation.
What interventions are being tested in trial NCT04242264?
The interventions under investigation include: Placebo (OTHER), Shigella sonnei strain 53G (BIOLOGICAL), WRSs2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04242264?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04242264 being conducted?
This trial has 2 study locations across Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shigella Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.